Sylvain Chemtob
Corporate Officer/Principal bei University of Montréal
Aktive Positionen von Sylvain Chemtob
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Montréal | Corporate Officer/Principal | 09.07.2009 | - |
McGill University | Corporate Officer/Principal | 16.04.2010 | - |
Karriereverlauf von Sylvain Chemtob
Ehemalige bekannte Positionen von Sylvain Chemtob
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Technik-/Wissenschafts-/F&E-Leiter | 09.07.2009 | 09.09.2013 |
Gründer | 16.04.2010 | 09.09.2013 |
Statistik
International
Kanada | 4 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sektoral
Consumer Services | 3 |
Distribution Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
- Börse
- Insiders
- Sylvain Chemtob
- Erfahrung